Beijing, Beijing, China The main office of represented VC is situated in the Beijing. The fund was located in Asia if to be more exact in China.
Among the most popular fund investment industries, there are Clinical Trials, Medical. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight Connect Biopharmaceuticals, Stemirna Therapeutics, Asieris Pharmaceuticals. The fund has exact preference in some founders of portfolio startups.
The usual cause for the fund is to invest in rounds with 4-5 partakers. Despite the Lapam Capital, startups are often financed by TF Capital, Qiming Venture Partners, XinYue Equity. The meaningful sponsors for the fund in investment in the same round are ZGC Group, Qiming Venture Partners, Zhongguancun VC Development Center. In the next rounds fund is usually obtained by Qiming Venture Partners, Northern Light Venture Capital, Cowin Capital.
The usual things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 30 percentage points more often commits exit comparing to other companies. The fund is generally included in 2-6 deals every year. The high activity for fund was in 2017.
Related Funds
Funds with similar focus
| Fund Name | Location |
| Ascend Venture Capital | Missouri, Saint Louis, United States |
| Bonaventure Capital | Alabama, Birmingham, United States |
| BrainLAB | Bayern, Germany, Munich |
| CD Capital | England, London, United Kingdom |
| CityBlock Capital | New York, New York, United States |
| CR Capital Management | Beijing, Beijing, China |
| Denshi-koen | Japan, Tokyo |
| Diaspora Angel Network | - |
| Gaea Technology | China, Guangdong, Shenzhen |
| Grosvenor Capital Management | Chicago, Illinois, United States |
| Investment Partners | Metuchen, New Jersey, United States |
| Keller Enterprises | Charlottesville, United States, Virginia |
| MSouth Equity Partners | Atlanta, Georgia, United States |
| Oryzn Capital | Israel, Tel Aviv, Tel Aviv |
| Pobox | - |
| Pod Investment | Stockholm, Stockholm County, Sweden |
| Taifu Capital | China, Shanghai |
| WILD Group Management | Switzerland, Zug, Zug |
| Yongjin Group | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
LTZ Therapeutics | $20M | 30 Jul 2024 | San Francisco, California, United States | ||
ReviR Therapeutics | $30M | 26 Jul 2024 | San Francisco, California, United States | ||
Rapafusyn Pharmaceuticals | $28M | 20 Jun 2024 | Baltimore, Maryland, United States | ||
Deyun Kangrui | $13M | 06 Feb 2023 | Wujiang, Jiangsu, China | ||
NeuShen Therapeutics | $20M | 29 Sep 2022 | Shanghai, Shanghai, China | ||
BridGene Biosciences | $38M | 27 Jul 2022 | Sunnyvale, California, United States | ||
Immunowake | $20M | 15 May 2022 | Birmingham, Alabama, United States | ||
Pleryon Therapeutics | $15M | 01 Apr 2022 | Shenzhen, Guangdong, China | ||
Chance Pharmaceuticals | $30M | 11 Oct 2021 | Hangzhou, Zhejiang, China |
– Ranok Therapeutics (Hangzhou) Co. Ltd. secured a $40m Series B funding round denominated in both U.S. dollars and Chinese yuan.
– The financing was led by Lapam Capital and Shanghai Healthcare Capital, with additional participation from Wu Capital, Zhongguancun Kaiyuan Capital and existing investors, and representatives of the new investors will join Ranok’s expanded board of directors.
– To date, Ranok has raised the equivalent of over $50m in funding.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
LTZ Therapeutics | $20M | 30 Jul 2024 | San Francisco, California, United States | ||
ReviR Therapeutics | $30M | 26 Jul 2024 | San Francisco, California, United States | ||
Rapafusyn Pharmaceuticals | $28M | 20 Jun 2024 | Baltimore, Maryland, United States | ||
Deyun Kangrui | $13M | 06 Feb 2023 | Wujiang, Jiangsu, China | ||
NeuShen Therapeutics | $20M | 29 Sep 2022 | Shanghai, Shanghai, China | ||
BridGene Biosciences | $38M | 27 Jul 2022 | Sunnyvale, California, United States | ||
Immunowake | $20M | 15 May 2022 | Birmingham, Alabama, United States | ||
Pleryon Therapeutics | $15M | 01 Apr 2022 | Shenzhen, Guangdong, China | ||
Chance Pharmaceuticals | $30M | 11 Oct 2021 | Hangzhou, Zhejiang, China |
